Pharmacyclics, Inc. (NASDAQ:PCYC)

CAPS Rating: 2 out of 5

A pharmaceutical company focused on the development of products that improve existing therapeutic approaches to cancer and other diseases.

Recs

0
Player Avatar spindlelady (65.83) Submitted: 11/14/2012 12:21:01 PM : Underperform Start Price: $49.31 PCYC Score: -4.69

The b-cell cancer drug they have in trial was found not to have positiveresults at the dosage being tested.

Featured Broker Partners


Advertisement